In vivo engineered cereblon protein

US10781239B2 · kind B2 · utility

Assignees

• Vividion Therapeutics, Inc. · US
• THE SCRIPPS RESEARCH INSTITUTE · US

Inventors

• David Weinstein · Dobbs Ferry, US
• Benjamin F. Cravatt · San Diego, US
• Matthew Patricelli · San Diego, US
• Dean Stamos · Carlsbad, US
• Gabe SIMON · San Diego, US
• Benjamin HORNING · San Diego, US
• Ekaterina VINOGRADOVA · San Antonio, US
• Brian NORDIN · San Diego, US
• Kristen BALTGALVIS · San Diego, US
• Todd Kinsella · Redwood City, US

Key dates

• Filing date: Aug 8, 2019
• Grant date: Sep 22, 2020
• Expiry date: Aug 8, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3.